Considerations for future trials in cerebral cavernous malformations
Lancet Neurol
.
2024 Oct;23(10):965.
doi: 10.1016/S1474-4422(24)00321-1.
Authors
Marco Cenzato
1
,
Ulrich Sure
2
,
Giuseppe Lanzino
3
,
Davide Boeris
4
,
Torstein Meling
5
,
Luca Regli
6
,
Andreas Gruber
7
,
Peter Vajkoczy
8
,
Michael Lawton
9
Affiliations
1
Department of Neurosurgery, Great Metropolitan Hospital Niguarda, Milan 20154, Italy. Electronic address:
[email protected]
.
2
Department of Neurosurgery, University Hospital Essen, University of Duisburg-Essen, Germany.
3
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
4
Department of Neurosurgery, Great Metropolitan Hospital Niguarda, Milan 20154, Italy.
5
Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark.
6
Department of Neurosurgery, University Hospital and University Zurich, Zurich, Switzerland.
7
Department of Neurosurgery and Clinical Research Institute of Neuroscience, Johannes Kepler University, Linz, Austria.
8
Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Germany.
9
Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
PMID:
39304258
DOI:
10.1016/S1474-4422(24)00321-1
No abstract available
Publication types
Letter
MeSH terms
Clinical Trials as Topic / methods
Hemangioma, Cavernous, Central Nervous System*
Humans